Literature DB >> 17576160

Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy.

Georgios Grammatikos1, Volker Teichgräber, Alexander Carpinteiro, Tanja Trarbach, Michael Weller, Ulrich R Hengge, Erich Gulbins.   

Abstract

Ceramide has been shown by many studies to induce apoptosis. Therefore, upregulation of ceramide is discussed as a novel approach for tumor treatment. However, it is unknown whether overexpression of acid sphingomyelinase releasing ceramide from sphingomyelin sensitizes cells to chemotherapy and, thus, serves as a potential target to amplify chemotherapy. Here, the authors demonstrate that transfection of human or murine glioma cells with acid sphingomyelinase results in a marked sensitization of glioma cells to gemcitabine and doxorubicin, respectively. Transfected cells responded to chemotherapy with an increased activation of acid sphingomyelinase, elevated ceramide levels, and approximately fourfold higher rates of cell death than control transfected cells. Neutralization of reactive oxygen species prevented these events. The data indicate a significant sensitization of glioma cells to chemotherapy treatment by expression of acid sphingomyelinase and further suggest an activation of acid sphingomyelinase by gemcitabine or doxorubicin, respectively, via reactive oxygen species.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576160     DOI: 10.1089/ars.2007.1673

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  20 in total

Review 1.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

2.  Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis.

Authors:  Justin M Snider; Magali Trayssac; Christopher J Clarke; Nicholas Schwartz; Ashley J Snider; Lina M Obeid; Chiara Luberto; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-12-20       Impact factor: 5.922

Review 3.  Cancer treatment strategies targeting sphingolipid metabolism.

Authors:  Babak Oskouian; Julie D Saba
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 4.  Lipid raft redox signaling: molecular mechanisms in health and disease.

Authors:  Si Jin; Fan Zhou; Foad Katirai; Pin-Lan Li
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

5.  Ceramide launches an acute anti-adhesion pro-migration cell signaling program in response to chemotherapy.

Authors:  Daniel Canals; Silvia Salamone; Bruno Jaime Santacreu; Erika Nemeth; Daniel Aguilar; María José Hernandez-Corbacho; Mohamad Adada; Daniela I Staquicini; Wadih Arap; Renata Pasqualini; John Haley; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2020-04-20       Impact factor: 5.191

Review 6.  Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.

Authors:  Catherine Pavoine; Françoise Pecker
Journal:  Cardiovasc Res       Date:  2009-01-28       Impact factor: 10.787

Review 7.  The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.

Authors:  Eric L Smith; Edward H Schuchman
Journal:  FASEB J       Date:  2008-06-20       Impact factor: 5.191

8.  Lysosomal ceramide mediates gemcitabine-induced death of glioma cells.

Authors:  Claudia A Dumitru; Ibrahim E Sandalcioglu; Marek Wagner; Michael Weller; Erich Gulbins
Journal:  J Mol Med (Berl)       Date:  2009-09-10       Impact factor: 4.599

9.  Apoptotic sphingolipid ceramide in cancer therapy.

Authors:  Wei-Ching Huang; Chia-Ling Chen; Yee-Shin Lin; Chiou-Feng Lin
Journal:  J Lipids       Date:  2011-01-13

10.  Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.

Authors:  Dorothee Gramatzki; Caroline Herrmann; Caroline Happold; Katrin Anne Becker; Erich Gulbins; Michael Weller; Ghazaleh Tabatabai
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.